Evidence map›Paper›PMID 36130929›Full record

ArticleNature communications2022

The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition.

Chihiro Motozono, Mako Toyoda, Toong Seng Tan, Hiroshi Hamana, Yoshihiko Goto, Yoshiki Aritsu, Yusuke Miyashita, Hiroyuki Oshiumi, Kimitoshi Nakamura, Seiji Okada and 4 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. IFN-γ derived from activated human CD4Scientific reports · 2024
    Article
  11. Article
  12. Article
  13. Two-Dimensional (2D) materials in the detection of SARS-CoV-2.Microchemical journal : devoted to the application of microtechniques in all branches of science · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Chihiro MotozonoDivision of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, 8600811, Japan. motozono@kumamoto-u.ac.jp.ORCID 0000-0002-9027-742X
Mako ToyodaDivision of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, 8600811, Japan.
Toong Seng TanDivision of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, 8600811, Japan.
Hiroshi HamanaDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, 9300194, Japan.ORCID 0000-0002-6964-1020
Yoshihiko GotoDivision of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, 8600811, Japan.
Yoshiki AritsuDepartment of Applied Chemistry, Faculty of Science and Engineering, Kindai University, Osaka, 577-8502, Japan.
Yusuke MiyashitaDepartment of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, 8608556, Japan.
Hiroyuki OshiumiDepartment of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, 8608556, Japan.ORCID 0000-0003-1567-8722
Kimitoshi NakamuraDepartment of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 8608556, Japan.
Seiji OkadaDivision of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, 8600811, Japan.ORCID 0000-0003-3124-5206
Keiko UdakaDepartment of Immunology, Kochi University, Kochi, 783-8505, Japan.
Mizuki KitamatsuDepartment of Applied Chemistry, Faculty of Science and Engineering, Kindai University, Osaka, 577-8502, Japan.
Hiroyuki KishiDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, 9300194, Japan.ORCID 0000-0002-8740-5371
Takamasa UenoDivision of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, 8600811, Japan. uenotaka@kumamoto-u.ac.jp.ORCID 0000-0003-4852-4236
Kumamoto University · JPKindai University · JPUniversity of Toyama · JPUniversity of Kochi · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the Omicron variant of the SARS-CoV-2 virus shows resistance to neutralizing antibody, it retains susceptibility to the cellular immune response. Here we characterize vaccine-induced T cells specific for various SARS-CoV-2 variants and identified HLA-A*24:02-restricted CD8

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralAntiviral AgentsCD8-Positive T-LymphocytesEpitopesHumansMutationReceptors, Antigen, T-CellSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralAntiviral AgentsEpitopesReceptors, Antigen, T-CellSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID36130929
PMCPMC9492656
OpenAlexW4296690669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.